Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor–induced bullous pemphigoid
Jordan T. Said, Jordan Talia, Erin X. Wei, Arash Mostaghimi, Yevgeniy R. Semenov, Anita Giobbie‐Hurder, Steven T. Chen, Nicole R. LeBoeuf
Topics & Concepts
MedicineBullous pemphigoidDermatologyDiscontinuationCancerPemphigoidRetrospective cohort studyPembrolizumabInternal medicineAdverse effectOncologyAntibodyImmunotherapyImmunologyAutoimmune Bullous Skin DiseasesCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways